Lepu Biopharma Co. Ltd. has out-licensed two preclinical T-cell engagers to Shanghai-based newco Excalipoint in a deal worth $857.5 million plus equity interest. Under the deal terms, Excalipoint gains an exclusive global license to CTM-012 and CTM-013, developed by Lepu’s Topabody T-cell engager platform. In exchange, Lepu will receive $10 million up front and up to $847.5 million in development and commercial-based milestones, plus tiered royalties on sales.
Systimmune Inc. has synthesized antibody-drug conjugates comprising antibodies targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to cytotoxic drugs through linker reported to be useful for the treatment of cancer.
Mabwell (Shanghai) Bioscience Co. Ltd. announced that its Cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC), 7MW-4911, has received IND clearance to initiate clinical trials from both the U.S. FDA and China's National Medical Products Administration (NMPA).
Beijing Tide Pharmaceutical Co. Ltd. has divulged nanobody-drug conjugates comprising a nanobody targeting B7 homolog 3 (B7-H3, CD276) covalently bound to exatecan through a linker reported to be useful for the treatment of lung cancer.
Beone Medicines (Beijing) Co. Ltd. has disclosed an antibody-drug conjugate comprising an antibody targeting fibroblast growth factor receptor 2 isoform 2 (FGFR2; FGFR2b) covalently linked to cytotoxic agent through a linker reported to be useful for the treatment of small-cell lung cancer (SCLC) and gastric cancer.
Simcere Zaiming Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates (ADC) comprising human monoclonal antibodies targeting zinc transporter ZIP6 (SLC39A6; LIV-1) covalently linked to cytotoxic drugs through a linker reported to be useful for the treatment of cancer.
The U.S. FDA has cleared Zymeworks Inc.’s IND application for ZW-251, a novel glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) incorporating the company’s proprietary topoisomerase 1 (TOPO1) inhibitor payload, ZD-06519, for the treatment of hepatocellular carcinoma (HCC).
Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 companies were from mainland China.
Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 companies were from mainland China.
Akari Therapeutics plc announced that it is continuing key research on its antibody-drug conjugate (ADC) payload PH1 to further demonstrate its ability to target cancers fueled by oncogenic drivers. PH1 is a spliceosome modulator designed to disrupt RNA splicing within cells. It binds spliceosome proteins SF3B1 and PH5α and targets normal splicing of pre-mRNA. PH1 is a spliceosome modulator designed to disrupt RNA splicing within cells. It binds spliceosome proteins SF3B1 and PH5α and targets normal splicing of pre-mRNA.
RSS
